The team at Charité – Universitätsmedizin Berlin is astounded by the huge improvement seen in a female patient with severe systemic lupus erythematosus (SLE) after being treated with the cancer medication teclistamab. Not long ago, the 23-year-old was wheelchair-bound due to the autoimmune disease.
How skeptical should you be of an after-the-fact subgroup analysis in a failed clinical trial?
This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.” Clinical trials of
October 31, 2023